{"product_id":"staar-bcg-matrix","title":"STAAR Surgical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO Visian ICL (Myopia)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric EVO ICL (Astigmatism)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICL Franchise in China and wider APAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. EVO ICL ramp post-approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory tailwind: U.S. market access enabled private-pay growth\u003c\/li\u003e\n\u003cli\u003eClinical edge: early adopters cite better night-vision and stability\u003c\/li\u003e\n\u003cli\u003eCommercial needs: training, co-marketing, financing\u003c\/li\u003e\n\u003cli\u003eBCG view: Star if execution maintains trajectory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon training + DTC demand engine (ICL ecosystem)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upfront spend, high lifetime value\u003c\/li\u003e\n\u003cli\u003eLaunch kits + training = faster surgeon adoption\u003c\/li\u003e\n\u003cli\u003eConsumer campaigns lower CAC as 2024 awareness compounds\u003c\/li\u003e\n\u003cli\u003eMachine sustains ICL refractive mindshare\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDouble-digit growth: APAC myopia surge and U.S. private-pay ramp\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.\u003c\/p\u003e\n\u003cp\u003eToric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence \u0026gt;50% in adults and 80–90% in school-aged cohorts sustains volume.\u003c\/p\u003e\n\u003cp\u003eHigh upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit growth\u003c\/td\u003e\n\u003ctd\u003eDouble-digit\u003c\/td\u003e\n\u003ctd\u003eCompany-reported 2024 trend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstigmatism prevalence\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003ctd\u003eAdult population\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC myopia\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% adults; 80–90% school-aged\u003c\/td\u003e\n\u003ctd\u003eRegional epidemiology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC market CAGR\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003eRefractive surgery market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Visian ICL models in mature markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICL delivery\/injector consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICL delivery\/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract IOL niche portfolio (select markets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNot a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R\u0026amp;D alongside 2024 company revenue of $186.5 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlanning and sizing tools\/licenses for ICL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePlanning and sizing tools\/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorkflow software relied on by clinics\u003c\/li\u003e\n\u003cli\u003eLow growth, high retention\u003c\/li\u003e\n\u003cli\u003eService-lite, high margin\u003c\/li\u003e\n\u003cli\u003eBundle sustains pricing power\u003c\/li\u003e\n\u003cli\u003eProduces incremental cash with minimal effort\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReplacement parts and accessories for ICL procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReplacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.\u003c\/p\u003e\n\u003cp\u003eProcurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.\u003c\/p\u003e\n\u003cp\u003eMargins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.\u003c\/p\u003e\n\u003cp\u003eThey quietly support the P\u0026amp;L month after month, providing recurring revenue stability beneath higher-growth portfolio items.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePredictable reorder cycles\u003c\/li\u003e\n\u003cli\u003eRoutine procurement post-onboarding\u003c\/li\u003e\n\u003cli\u003eScale-enhanced margins\u003c\/li\u003e\n\u003cli\u003eReliable recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICLs + consumables drove \u003cstrong\u003e$186.5M\u003c\/strong\u003e; implants \u003cstrong\u003e+20%\u003c\/strong\u003e YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R\u0026amp;D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses \u0026gt;70% attach, \u0026gt;80% renewals; consumables\/replacement parts deliver high-margin recurring revenue with low promo spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$186.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICL volume growth\u003c\/td\u003e\n\u003ctd\u003e~20% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense attach\/renew\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% \/ \u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163652829561,"sku":"staar-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/staar-bcg-matrix.png?v=1762722090","url":"https:\/\/portersfiveforce.com\/products\/staar-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}